Few areas of peptide research have moved faster in the last several years than incretin-pathway compounds — the GLP-1 receptor agonists and their multi-receptor successors. Here's a grounded overview of what's actually being studied and why these compounds are structured the way they are.

The core mechanism

GLP-1 (glucagon-like peptide-1) is an incretin hormone naturally released in the gut in response to food intake. It signals through the GLP-1 receptor to influence insulin secretion, gastric emptying, and satiety signaling. Research-grade GLP-1 receptor agonists are synthetic analogs designed to activate this same pathway with a longer half-life than the native hormone, which degrades within minutes.

Single vs. multi-receptor agonists

Research in this space has moved beyond single-target GLP-1 agonism. Tirzepatide is a dual agonist, targeting both the GIP and GLP-1 receptors — research interest here centers on whether combined incretin pathway activation produces effects beyond either pathway alone. Retatrutide goes a step further as a triple agonist, additionally targeting the glucagon receptor (GCGR), and is one of the most closely watched compounds in current metabolic research for exactly that reason.

Retatrutide vs. semaglutide: what the body composition data shows

Total weight loss is only part of the picture — how much of that loss is fat versus lean mass is a separate, and increasingly closely-watched, research question. Two recent DEXA (dual-energy X-ray absorptiometry) substudies give a useful comparison, though it's worth noting upfront that they were run in different populations, so this is informative rather than a perfectly matched head-to-head.

Semaglutide — STEP 1 substudy (general population with overweight/obesity, 68 weeks): total body weight decreased 15.0% versus 3.6% with placebo. Of that, total fat mass dropped 19.3% and visceral fat mass dropped 27.4% from baseline. Lean body mass decreased 9.7% — but because fat mass fell faster than lean mass, lean mass as a proportion of total body mass actually increased by about 3 percentage points over the study.

Retatrutide — Lancet Diabetes & Endocrinology substudy (population with type 2 diabetes, 36 weeks): across the studied doses, roughly 75–80% of total weight lost was fat mass, with the remaining 20–25% coming from lean mass — a ratio the study authors noted was in line with other obesity treatments, despite retatrutide's larger overall weight loss.

Read together, both compounds show the expected pattern of fat loss substantially outpacing lean mass loss, rather than a proportional loss across all tissue types. The retatrutide substudy population (type 2 diabetes) differs from the semaglutide STEP 1 population (general overweight/obesity without a diabetes requirement), so researchers designing comparative protocols should account for that population difference rather than treat the two figures as directly interchangeable.

Which is "better" depends on the research question

It's tempting to look at retatrutide's larger headline weight-loss figures and its favorable fat-to-lean ratio and conclude it simply outperforms semaglutide across the board. That's not quite the full picture. The two studies didn't just involve different populations — they ran for different durations too (36 weeks for the retatrutide substudy versus 68 weeks for STEP 1), and they were designed around different mechanistic questions. Semaglutide's single-receptor GLP-1 pathway has a much longer research track record across broader population types, including people without diabetes. Retatrutide's added GIP and glucagon receptor engagement is specifically what researchers point to when investigating hepatic and thermogenic contributions to metabolic outcomes — a distinct research question from pure incretin-pathway signaling.

Put simply: neither compound is straightforwardly "better" in the abstract. Which one fits a given protocol depends on the pathway, population, and research question it's designed around. We'd rather lay out the actual data, with its caveats, than oversimplify it for you — you're in the best position to judge which compound fits your research once you have the full picture.

Sources: Lancet Diabetes & Endocrinology — retatrutide body composition substudy; Journal of the Endocrine Society — STEP 1 semaglutide body composition analysis.

What research typically examines

Studies involving this compound class generally focus on receptor binding characteristics, downstream signaling pathways, comparative pharmacokinetics between analogs, and metabolic model systems examining insulin sensitivity and energy balance regulation.

Sourcing considerations

Because these are larger, more structurally complex peptides than many single-chain research compounds, purity verification matters even more.See our guide to reading a COA for what to check before you order.